SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals

Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Andrea, Consonni, Dario, Oggioni, Massimo, Bono, Patrizia, Renteria, Sara U., Piatti, Alessandra, Pesatori, Angela C., Castaldi, Silvana, Muscatello, Antonio, Riboldi, Luciano, Ceriotti, Ferruccio, Bandera, Alessandra, Gori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285930/
https://www.ncbi.nlm.nih.gov/pubmed/34293641
http://dx.doi.org/10.1016/j.jiph.2021.07.005
_version_ 1783723644447358976
author Lombardi, Andrea
Consonni, Dario
Oggioni, Massimo
Bono, Patrizia
Renteria, Sara U.
Piatti, Alessandra
Pesatori, Angela C.
Castaldi, Silvana
Muscatello, Antonio
Riboldi, Luciano
Ceriotti, Ferruccio
Bandera, Alessandra
Gori, Andrea
author_facet Lombardi, Andrea
Consonni, Dario
Oggioni, Massimo
Bono, Patrizia
Renteria, Sara U.
Piatti, Alessandra
Pesatori, Angela C.
Castaldi, Silvana
Muscatello, Antonio
Riboldi, Luciano
Ceriotti, Ferruccio
Bandera, Alessandra
Gori, Andrea
author_sort Lombardi, Andrea
collection PubMed
description Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history of nasopharyngeal swab (NPS) and symptoms. Among 3475 HCWs the highest titres were recorded among those infected more than 6 months before vaccination, independently of symptoms, followed by those infected less than 6 months before vaccination, especially in those with symptoms, and by uninfected HCWs. Vaccination with BNT162b2 can boost immunity acquired through infection, particularly in those infected more than 6 months before vaccination.
format Online
Article
Text
id pubmed-8285930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
record_format MEDLINE/PubMed
spelling pubmed-82859302021-07-20 SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals Lombardi, Andrea Consonni, Dario Oggioni, Massimo Bono, Patrizia Renteria, Sara U. Piatti, Alessandra Pesatori, Angela C. Castaldi, Silvana Muscatello, Antonio Riboldi, Luciano Ceriotti, Ferruccio Bandera, Alessandra Gori, Andrea J Infect Public Health Article Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history of nasopharyngeal swab (NPS) and symptoms. Among 3475 HCWs the highest titres were recorded among those infected more than 6 months before vaccination, independently of symptoms, followed by those infected less than 6 months before vaccination, especially in those with symptoms, and by uninfected HCWs. Vaccination with BNT162b2 can boost immunity acquired through infection, particularly in those infected more than 6 months before vaccination. The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021-08 2021-07-17 /pmc/articles/PMC8285930/ /pubmed/34293641 http://dx.doi.org/10.1016/j.jiph.2021.07.005 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lombardi, Andrea
Consonni, Dario
Oggioni, Massimo
Bono, Patrizia
Renteria, Sara U.
Piatti, Alessandra
Pesatori, Angela C.
Castaldi, Silvana
Muscatello, Antonio
Riboldi, Luciano
Ceriotti, Ferruccio
Bandera, Alessandra
Gori, Andrea
SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title_full SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title_fullStr SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title_full_unstemmed SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title_short SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
title_sort sars-cov-2 anti-spike antibody titres after vaccination with bnt162b2 in naïve and previously infected individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285930/
https://www.ncbi.nlm.nih.gov/pubmed/34293641
http://dx.doi.org/10.1016/j.jiph.2021.07.005
work_keys_str_mv AT lombardiandrea sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT consonnidario sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT oggionimassimo sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT bonopatrizia sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT renteriasarau sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT piattialessandra sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT pesatoriangelac sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT castaldisilvana sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT muscatelloantonio sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT riboldiluciano sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT ceriottiferruccio sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT banderaalessandra sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals
AT goriandrea sarscov2antispikeantibodytitresaftervaccinationwithbnt162b2innaiveandpreviouslyinfectedindividuals

Ejemplares similares